You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 24, 2024

~ Buy the GATTEX KIT (teduglutide recombinant) Drug Profile, 2024 PDF Report in the Report Store ~

GATTEX KIT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Gattex Kit, and when can generic versions of Gattex Kit launch?

Gattex Kit is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has eight patent family members in seven countries.

The generic ingredient in GATTEX KIT is teduglutide. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the teduglutide profile page.

DrugPatentWatch® Generic Entry Outlook for Gattex Kit

Gattex Kit was eligible for patent challenges on December 21, 2016.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 16, 2026. This may change due to patent challenges or generic licensing.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for GATTEX KIT?
  • What are the global sales for GATTEX KIT?
  • What is Average Wholesale Price for GATTEX KIT?
Drug patent expirations by year for GATTEX KIT
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for GATTEX KIT
Generic Entry Date for GATTEX KIT*:
Constraining patent/regulatory exclusivity:
TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH SHORT BOWEL SYNDROME (SBS) WHO ARE DEPENDENT ON PARENTERAL SUPPORT
NDA:
Dosage:
POWDER;SUBCUTANEOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for GATTEX KIT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Allegheny Singer Research InstitutePhase 3
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)Phase 3
Daniel Dante YehPhase 2

See all GATTEX KIT clinical trials

Pharmacology for GATTEX KIT
Paragraph IV (Patent) Challenges for GATTEX KIT
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
GATTEX KIT Injection teduglutide 5 mg/vial 203441 1 2016-12-21

US Patents and Regulatory Information for GATTEX KIT

GATTEX KIT is protected by two US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of GATTEX KIT is ⤷  Subscribe.

This potential generic entry date is based on TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH SHORT BOWEL SYNDROME (SBS) WHO ARE DEPENDENT ON PARENTERAL SUPPORT.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa GATTEX KIT teduglutide POWDER;SUBCUTANEOUS 203441-001 Dec 21, 2012 RX Yes Yes 7,847,061*PED ⤷  Subscribe Y ⤷  Subscribe
Takeda Pharms Usa GATTEX KIT teduglutide POWDER;SUBCUTANEOUS 203441-001 Dec 21, 2012 RX Yes Yes 9,060,992*PED ⤷  Subscribe Y ⤷  Subscribe
Takeda Pharms Usa GATTEX KIT teduglutide POWDER;SUBCUTANEOUS 203441-001 Dec 21, 2012 RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for GATTEX KIT

See the table below for patents covering GATTEX KIT around the world.

Country Patent Number Title Estimated Expiration
Japan 2008518941 ⤷  Subscribe
European Patent Office 1809318 TRAITEMENT DE PATIENTS ATTEINTS DU SYNDROME DE L'INTESTIN COURT AVEC COLON EN CONTINUITE (TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY) ⤷  Subscribe
Japan 4149497 ⤷  Subscribe
World Intellectual Property Organization (WIPO) 9632414 ⤷  Subscribe
Hong Kong 1147761 ⤷  Subscribe
Mexico 9707949 PEPTIDO-2 SEMEJANTE AL GLUCAGON Y SU USO TERAPEUTICO. (GLUCAGON-LIKE PEPTIDE-2 AND ITS THERAPEUTIC USE.) ⤷  Subscribe
Japan 5197012 ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for GATTEX KIT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0906338 2013/006 Ireland ⤷  Subscribe PRODUCT NAME: TEDUGLUTIDE; REGISTRATION NO/DATE: EU/1/12/787/001 20120830
0906338 CA 2013 00012 Denmark ⤷  Subscribe
0906338 13C0013 France ⤷  Subscribe PRODUCT NAME: TEDUGLUTIDE; REGISTRATION NO/DATE: EU/1/12/787/001 20120830
0906338 C300578 Netherlands ⤷  Subscribe PRODUCT NAME: TEDUGLUTIDE OR A PHARMACEUTICALLY ACCEPTABLE FORM THEREOF; REGISTRATION NO/DATE: EU/1/12/787/001 20120830
0906338 92153 Luxembourg ⤷  Subscribe PRODUCT NAME: TEDUGLUTIDE SOUS TOUTES SES FORMES, TELLES QU ELLES SONT PROTEGEES PAR LE BREVET DE BASE
0906338 1390009-7 Sweden ⤷  Subscribe PRODUCT NAME: TEDUGLUTID; REG. NO/DATE: EU/1/12/787/001 20120830
0906338 433 Finland ⤷  Subscribe
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

GATTEX KIT Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of GATTEX (Teduglutide)

Introduction to GATTEX

GATTEX, also known as teduglutide, is a groundbreaking therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. This drug has significantly impacted the market dynamics and financial trajectory of the SBS treatment sector.

Approval and Regulatory Landscape

GATTEX was approved by the FDA in December 2012 for subcutaneous use in adult patients with SBS. It received orphan drug designation from both the FDA and the European Medicines Agency (EMA), highlighting its importance in treating a rare and debilitating condition[3].

Market Drivers

Growing Prescriptions

The increasing prescriptions of GATTEX in the U.S. and its European counterpart, Revestive, have been a major driver of the SBS market growth. These drugs have shown significant efficacy in reducing the need for parenteral nutrition (PN) and intravenous (IV) support, improving the quality of life for SBS patients[1].

Clinical Efficacy

Clinical trials, such as the STEPS and STEPS-2 studies, have demonstrated the effectiveness of GATTEX. For instance, in the STEPS trial, 63% of patients treated with GATTEX achieved a 20% or greater reduction in weekly PN/IV volume compared to 30% for the placebo group. This clinical success has bolstered the drug's market position[3][5].

Reimbursement and Access

Efficient reimbursement scenarios in North America and Europe have further boosted the market for GATTEX. NPS Pharmaceuticals, the original developer, and later Takeda, after acquiring NPS, have worked closely with payers to ensure access to this critical therapy. Programs like NPS Advantage have helped patients navigate the reimbursement landscape, enhancing the drug's adoption[3].

Financial Performance

Revenue Growth

The approval and subsequent launch of GATTEX have contributed significantly to the revenue growth of the companies involved. For example, NPS Pharmaceuticals' acquisition by Shire (now part of Takeda) was partly driven by the potential of GATTEX. Shire's strong revenue growth, including a 9% increase in product sales in 2015, was partly attributed to the performance of GATTEX and other acquired products[2].

Market Share

Takeda Pharmaceutical Company, which acquired Shire and thus the rights to GATTEX, holds the largest market share in the SBS market. The company's robust R&D investments and strategic acquisitions have solidified its position, with GATTEX being a key contributor to its market dominance[4].

Competitive Landscape

Key Players

The SBS market is competitive, with several pharmaceutical giants operating in the space. Besides Takeda, other notable players include Merck KGaA, Emmaus Life Sciences, Inc., Nutrinia Ltd, GlyPharma Therapeutics, OxThera, and Ardelyx, Inc. However, Takeda's strong focus on R&D and its extensive pipeline have kept it at the forefront[1][4].

Market Segmentation and Growth

GLP-2 Segment Dominance

The GLP-2 segment, which includes GATTEX, dominates the SBS market due to the presence of approved products and a robust pipeline. The increasing penetration of GLP-2 drugs among SBS patients and awareness programs by various organizations are expected to drive market growth[4].

Regional Growth

North America, particularly the U.S., holds the largest market share for SBS treatments, driven by the high adoption of GATTEX. Europe follows closely, with Revestive being the highest-grossing drug in the region. The Asia Pacific region is expected to register the highest CAGR during the forecast period due to rising awareness and R&D investments[1][4].

Challenges and Limitations

Cost and Reimbursement

Despite its efficacy, GATTEX is considered expensive, which limits its adoption in some regions. The lack of reimbursement policies in countries like India and Africa further hampers market growth. However, the growing number of online and retail pharmacies, especially in the U.S. and Europe, is helping to mitigate some of these challenges[4].

Future Outlook

Market Projections

The global SBS market, driven by drugs like GATTEX, is projected to grow from $1.42 billion in 2024 to $2.60 billion by 2032, at a CAGR of 7.9%. The increasing demand for GLP-2 drugs and the expanding distribution networks of major players are expected to fuel this growth[4].

Pipeline and R&D

Takeda and other key players continue to invest heavily in R&D, focusing on developing new drugs and biologics for SBS. This ongoing innovation is expected to further enhance the market's growth trajectory and provide more treatment options for patients[2][4].

Key Takeaways

  • Approval and Efficacy: GATTEX was approved by the FDA in 2012 and has shown significant clinical efficacy in reducing PN/IV volume.
  • Market Drivers: Growing prescriptions, efficient reimbursement, and strong clinical performance are key drivers.
  • Financial Performance: The drug has contributed to the revenue growth of companies like NPS Pharmaceuticals and Takeda.
  • Competitive Landscape: Takeda holds the largest market share, with a strong focus on R&D and strategic acquisitions.
  • Market Segmentation: The GLP-2 segment dominates, with North America and Europe being the largest markets.
  • Challenges: High cost and limited reimbursement policies in some regions are significant challenges.
  • Future Outlook: The market is projected to grow significantly, driven by increasing demand for GLP-2 drugs and expanding distribution networks.

FAQs

What is GATTEX used for?

GATTEX (teduglutide) is used for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support.

Who approved GATTEX?

GATTEX was approved by the U.S. Food and Drug Administration (FDA) in December 2012.

What are the key clinical findings of GATTEX?

In clinical trials, GATTEX has shown that 63% of patients achieved a 20% or greater reduction in weekly PN/IV volume, and 54% reduced the number of infusion days per week by one or more days[3][5].

Which company holds the largest market share for GATTEX?

Takeda Pharmaceutical Company holds the largest market share for GATTEX, following its acquisition of Shire and NPS Pharmaceuticals[4].

What are the challenges facing the adoption of GATTEX?

High cost and limited reimbursement policies in some regions are significant challenges to the adoption of GATTEX[4].

What is the projected market growth for SBS treatments like GATTEX?

The global SBS market is projected to grow from $1.42 billion in 2024 to $2.60 billion by 2032, at a CAGR of 7.9%[4].

Sources

  1. Global Short Bowel Syndrome Market, 2017 to 2025: Growing Prescriptions of Gattex and Revestive in U.S. and Europe Respectively is Boosting the Growth of the Market. Globenewswire.
  2. Shire delivers strong revenue growth and cash generation. Takeda.
  3. FDA Approves Gattex® (teduglutide [rDNA Origin]) for Injection for the Treatment of Adult Short Bowel Syndrome. PR Newswire.
  4. Short Bowel Syndrome Market Size, Share, Growth Report, 2032. Fortune Business Insights.
  5. GATTEX® (teduglutide) Results in Adults With Short Bowel Syndrome. Gattex.com.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.